AUS
NZ
UK
CA
USA
IND
Healt
Ramsay Health Care Limited (ASX:RHC) Price-to-Earnings Ratio: A Closer Look
September 19, 2024 10:30 AM AEST| By Team Kalkine MediaRamsay Health Care Limited (ASX:RHC) currently holds a price-to-earnings (P/E) ratio of 36.3x, significantly higher than the market average in Australia, where nearly half of the listed companies trade below a P/E ratio of 19x. On the surface, this e...
Does LuPSMA Represent a Breakthrough in Treating Metastatic Prostate Cancer?
September 18, 2024 04:20 PM AEST| By Team Kalkine MediaA significant study conducted by the,Peter MacCallum Cancer Centre,(Peter Mac) has demonstrated the potential of targeted radioactive infusion for enhancing treatment outcomes in metastatic prostate cancer, with implications for earlier-stage disease...
FDA Provides Guidance for Paradigm Biopharma's Phase 3 Osteoarthritis Trial: A Closer Look
September 18, 2024 10:27 AM AEST| By Team Kalkine MediaParadigm Biopharmaceuticals (ASX:PAR) has received significant feedback from the U.S. Food and Drug Administration (FDA) regarding its Phase 3 clinical trial for knee osteoarthritis. The FDA's recent communication highlights a need for adjustments to...
Botanix Pharmaceuticals Ltd (ASX: BOT) to Launch Sofdra for Excessive Sweating in the US
September 17, 2024 06:09 PM AEST| By Team Kalkine MediaBotanix Pharmaceuticals Ltd (ASX: BOT) has announced an upcoming launch of its approved product, Sofdra, for treating primary axillary hyperhidrosis (PAH), a condition causing excessive sweating. The product is expected to hit the US market in the Ma...
Pacific Smiles Group (ASX:PSQ) Receives New Takeover Offer from Beam Dental Bidco
September 17, 2024 10:37 AM AEST| By Team Kalkine MediaPacific Smiles Group Ltd (ASX:PSQ), a prominent dental centre operator in Australia, has recently received an off-market takeover proposal from Beam Dental Bidco Pty Ltd, an unlisted Australian entity. Beam Dental Bidco is associated with Genesis Cap...
Dimerix (ASX: DXB) Partners with UK’s RaDaR to Advance FSGS Treatment
September 16, 2024 08:23 PM AEST| By Team Kalkine MediaDimerix,(ASX: DXB),has recently announced a significant collaboration with the UK’s National Registry of Rare Kidney Diseases (RaDaR) to enhance its ACTION3 Phase 3 clinical trial for DMX-200, aimed at treating focal segmental glomerulosclerosis (FSG...
ResMed CDI (ASX: RMD) Sees Strong 2024 Performance: A Closer Look
September 16, 2024 06:10 PM AEST| By Team Kalkine MediaThe share price of ResMed CDI,(ASX: RMD),has surged by 45.3% since the beginning of 2024. This substantial increase has drawn attention to the company’s performance and potential.,RMD Share Price Overview,Founded in 1989 by Peter Farrell, ResMed orig...
Regis Healthcare Ltd (ASX: REG) Sees Impressive Gains: What Does the Price-to-Sales Ratio Reveal?
September 13, 2024 02:23 PM AEST| By Team Kalkine MediaRegis Healthcare Ltd,(ASX: REG),has seen a remarkable 31% increase in its share price over the past month, contributing to an impressive 112% annual gain. This surge has certainly caught the attention of investors.,Despite this strong performance, th...
BlinkLab (ASX: BB1) Partners with INTER-PSY to Advance Autism Diagnosis
September 12, 2024 06:33 PM AEST| By Team Kalkine MediaBlinkLab has embarked on a significant partnership with INTER-PSY to advance the capabilities of its autism diagnostic platform. This collaboration aims to optimize BlinkLab's experimental and AI algorithms, facilitating the path to regulatory approv...
CSL Ltd (ASX: CSL) Shares Up 4% in 2024: Should They Be on Your Radar?
September 12, 2024 02:42 PM AEST| By Team Kalkine MediaCSL Ltd has seen its share price climb 4.0% since the beginning of 2024. As an,ASX healthcare stock,, this rise reflects the company’s ongoing commitment to developing innovative medicines that address critical health needs and contribute to improved...
GTI extends uranium mineralisation at Lo Hema through development drilling
September 12, 2024 01:18 PM AEST| By Team Kalkine MediaClarity Pharmaceuticals Ltd (ASX:CU6) has announced progress in its ongoing SECuRE trial, with positive safety results from the latest stage. The trial focuses on prostate cancer treatment using Cu-SAR-bisPSMA, targeting prostate-specific membrane an...
Dimerix Begins Phase 3 Recruitment for Kidney Disease Study in Mexico
September 12, 2024 11:15 AM AEST| By Team Kalkine MediaDimerix Limited (ASX:DXB) has announced the commencement of patient recruitment for its ‘ACTION3’ Phase 3 clinical trial. This significant milestone involves enrolling adolescent patients aged 12 to 17 with kidney disease in Mexico. The selection of...
Pro Medicus Limited (ASX: PME): Why the Surge in Share Price?
September 10, 2024 02:13 PM AEST| By Team Kalkine MediaThe Pro Medicus Limited,(ASX: PME),share price has experienced a remarkable 63.6% increase since the beginning of 2024. This impressive rise in value highlights the growing interest in PME shares and raises the question of what is driving this surge....
Noxopharm Obtains $1.8 Million in Funding Ahead of R&D Rebate
September 09, 2024 02:19 PM AEST| By Team Kalkine MediaNoxopharm Ltd,(ASX:NOX),has secured $1.8 million in advanced funding through a secured loan agreement with Endpoints Capital Pty Ltd, a specialist in R&D finance for the life sciences sector. This loan is backed by an anticipated rebate from the Aust...
CSL Ltd and Pro Medicus Limited: Current Performance and Key Insights
September 09, 2024 01:53 PM AEST| By Team Kalkine MediaAs the year progresses, CSL Ltd and Pro Medicus Limited are making significant strides in their respective sectors. CSL Ltd, an,ASX healthcare stock,, has experienced a notable rise in its share price, reflecting its robust position in the biotechnol...
Exploring the Latest Developments in RMD Shares
September 06, 2024 04:06 PM AEST| By Team Kalkine MediaResMed CDI has been on a remarkable upward trajectory in 2024, with its share price surging 42.6% since the start of the year. Investors are taking a keen interest in RMD shares,(ASX:RMD),, and several factors are contributing to this impressive perf...
Breakthroughs in Coronary Disease Indicate Potential Future Reduction in Deaths
September 06, 2024 02:47 PM AEST| By Team Kalkine MediaCoronary disease remains the leading cause of death in Australia, accounting for about 24% of all fatalities. While the World Health Organisation estimates that approximately 17.9 million people worldwide succumb to coronary diseases annually, recent...
Orthocell Products Enter Canadian Market with Initial Sale via Partner BioHorizons
September 06, 2024 02:21 PM AEST| By Team Kalkine MediaOrthocell Ltd,(ASX: OCC,), has advanced its global market expansion by making its debut in the Canadian biotech sector with the first sale of its products through distribution partner BioHorizons. This milestone marks a significant step in Orthocell’...
Immuron Receives Positive Feedback from US FDA Ahead of IMM-529 Investigational New Drug Application
September 06, 2024 02:20 PM AEST| By Team Kalkine MediaImmuron Ltd,(ASX:IMC),has received positive feedback from the United States Food and Drug Administration (FDA) regarding its IMM-529 product, aimed at preventing or treating Clostridioides difficile infection (CDI). This feedback follows a pre-IND (I...
Biotron Ltd (ASX:BIT) Faces Backlash Over Disappointing COVID Drug Trial Results
September 06, 2024 01:34 PM AEST| By Team Kalkine MediaBiotron Ltd,(ASX:BIT),is under scrutiny following the results of its latest trial for its COVID-19 drug, BIT225-012. The trial results, which were eagerly anticipated, have not met the expectations of shareholders and have been met with frustration o...
Advertise your brand on Kalkine Media